<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00492687</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000551555</org_study_id>
    <secondary_id>POHA-0601</secondary_id>
    <nct_id>NCT00492687</nct_id>
  </id_info>
  <brief_title>Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas</brief_title>
  <official_title>A Phase II Pilot Trial of Radiation Therapy With Concurrent and Adjuvant Temozolomide, Tamoxifen and Carboplatin (T2C) in the Treatment of Patients With Primary Central Nervous System Malignant Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Diego Pacific Oncology &amp; Hematology Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in&#xD;
      chemotherapy, such as temozolomide and carboplatin, work in different ways to stop the growth&#xD;
      of tumor cells, either by killing the cells or by stopping them from dividing. Tamoxifen may&#xD;
      make tumor cells more sensitive to radiation therapy and chemotherapy. Giving radiation&#xD;
      therapy together with temozolomide, tamoxifen, and carboplatin may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects and how well giving radiation&#xD;
      therapy together with temozolomide, tamoxifen, and carboplatin works in treating patients&#xD;
      with malignant gliomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the progression-free and overall survival of patients with supratentorial&#xD;
           malignant gliomas (WHO grade III or IV) receiving radiotherapy with concurrent and&#xD;
           adjuvant temozolomide, tamoxifen citrate, and carboplatin.&#xD;
&#xD;
        -  Determine the acute and delayed treatment-related toxicities in these patients.&#xD;
&#xD;
        -  Determine tumor response in patients with postoperative measurable disease.&#xD;
&#xD;
      OUTLINE: This is an open-label, pilot study.&#xD;
&#xD;
        -  Induction therapy: Patients receive oral temozolomide twice daily and oral tamoxifen&#xD;
           citrate twice daily on days 1-42 and carboplatin IV over 60 minutes on days 1, 8, 15,&#xD;
           22, 29, and 36. Patients also receive radiotherapy on days 1-5 in weeks 1-6.&#xD;
&#xD;
        -  Consolidation therapy: Beginning 4 weeks after the completion of induction therapy,&#xD;
           patients receive temozolomide, tamoxifen citrate, and carboplatin as in induction&#xD;
           therapy. Treatment repeats every 8 weeks for up to 4 courses in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2006</start_date>
  <primary_completion_date type="Anticipated">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor response</measure>
  </primary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed glioblastoma multiforme and/or anaplastic astrocytoma&#xD;
&#xD;
               -  Supratentorial tumor&#xD;
&#xD;
               -  No well-differentiated astrocytoma or glioma with oligodendroglial component&#xD;
&#xD;
               -  No multifocal glioma&#xD;
&#xD;
          -  Has undergone surgery within the past 6 weeks&#xD;
&#xD;
          -  No recurrent glioblastoma multiforme&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Neurological functional status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  ANC ≥ 1,200/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Blood urea nitrogen ≤ 1.5 times ULN&#xD;
&#xD;
          -  Total and direct bilirubin ≤ 3 times ULN&#xD;
&#xD;
          -  AST and ALT ≤ 3 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 3 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             completion&#xD;
&#xD;
          -  No other malignancies within the past 3 years, except for carcinoma in situ of the&#xD;
             cervix or nonmelanoma skin cancer&#xD;
&#xD;
          -  No acquired immune deficiency syndrome (AIDS)&#xD;
&#xD;
          -  No major medical illness or psychiatric impairment that would preclude study&#xD;
             compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior radiotherapy to the head and neck&#xD;
&#xD;
          -  No other concurrent therapy for the tumor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward F. McClay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Diego Pacific Oncology &amp; Hematology Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Diego Pacific Oncology and Hematology Associates, Incorporated - Encinitas</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward F. McClay, MD</last_name>
      <phone>760-452-3340</phone>
      <email>emcclay@pacificoncology.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2007</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

